1Saal S, Harvey SJ. MicroRNAs and the kidney:coming of age [ J ]. Curr Opin Nephrol Hypertens,2009 ( 18 ) :317-323.
2Zhang Y, Liu D, Chen X, et al. Secreted monocylic miR-150 en- hances targeted endothelial cell migration [ J 1. Mol Cell ,2010 (39) : 133-144.
3Shah AA, Leidinger P, Blin N, et al. miRNA : small molecules as po- tential novel biomarkers in cancer[J]. Curr Med Chen,2010,17 ( 36 ) :4427-4432.
4Scholer N, Langer C, Dohner H, et al. Serum microRNAs as a no- vel class of biomarkers:a comprehensive review of the literature [ J 1. Exp Hematol,2010,38 (12) : 1126-1130.
5Bhatt K, Mi QS, Dong Z. mieroRNAs in kidneys : biogenesis, regu- lation, and pathophysiological roles[ J ]. Am J Physiol Renal Physi- ol,2011,300(3) :F602-F610.
6Lorenzen JM, Hailer H, Thum T. MicroRNAs as mediators and therapeutic targets in chronic kidney disease [ J ]. Nat Rev Nephrol, 2011,7 ( 5 ) :286-294.
7Wessely O, Agrawal R, Tran U. MicroRNAs in kidney develop- ment : lessons from the frog[J]. RNA Biol, 2010,7 (3) :296-299.
8Patel V, Williams D, Hajarnis S, et al. miR-17 -92 miRNA clus- ter promotes kidney cyst growth in polycystie kidney disease [ J ].Proe Natl Aead Sei USA,2013,110 (26) : 10765-10770.
9Jazbutyte V, Thum T. MieroRNA-21 : from cancer to cardiovascular disease [ J 1. Curr Drug Targets, 2010,11 ( 8 ) :926-935.
10Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic acti- vation of pulmonary fibroblasts and lung fibrosis [J]. J Exp Med, 2010,207(8) :1589-1597.
二级参考文献24
1CHIARELLI F,GASPARI S,MARCOVECCHIO M L.Role of growth factors in diabetic kidney disease[J].Horm Metab Res,2009,41(8):585-593.
2ZIYADDH F N.Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy[J].Diabetes Res Clin Pract,2008,13(82)38-41.
3SUZUKI S,TANAKA Y,ORITO E,et al.Transforming growth factor-beta-1 genetic polymorphism in Japanese patients with chronic hepatitis C virus infection[J].J Gastroenterol Hepatol,2003,18(10):1139-1143.
4XU H Y,HOU X W,WANG L F,et al.Association between transforming growth factor beta1 polymorphisms and left ventricle hypertrophy in essential hypertendive subjects[J].Mol Cell Biochem,2010,335(1/2):13-17.
5PHILLIPS J A,POLING J S,PHILLIPS C A,et al.Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension[J].Genet Med,2008,10(5):359-365.
6KAWANO H,KIM S,OHTA K,er al.Differential contribution of three mitogen-activated protein kinases to PDGF-BB-induced messagial cell proliferation and gene expression[J].J Am Soc Nephrol,2003,14(3):584-592.
7GEWALTIG J,MANGASSER STEPHAN K,GARTUNG C,et al.Association of polymirphisms of the transforming growth factor-β1 gene with the rate of progression of HCV-induced liver fibrosis[J].Clin Chim Acta,2002,316(1):83-89.
8PONCELET A C,SCHNAPER H W.Regulation of hum an mesangial cell collagen expression by transforming growth factor-β1[J].Am J Physiol Renal Physiol,1998,275(32):458-466.
9MISHRA R,ZHU L,ECKERT R L,et al.TGF-beta-regulated collagen type 1 accumulation role of Src-based signals[J].Am J Physiol cell Physilo,2007:292(4):1361-1369.
10SHIHAB F S,YAM AMOTO T,BORDER W A,et al.Transforning growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts[J].Am Soc Nephrol,1995,6(2):286-294.
6Chobanian AV, Bakfis GL, Black HR, et al. TheSeventh Report of the Joint National Committee onPrevention, Detection, Evaluation, and Treatment of High Blood Pressure : the JNC 7 report [ J ]. JAMA, 2012,289 ( 19 ) :2560-2572.
7Butler R, Morris AD, Belch JJ, et al. Allopurinolnormalizes endothe- lial dysfunction in type 2 diabeticswith mild hypertension [ J ]. Hy- pertension,2013,35 (3) :746-751.
8Perlstein TS, Gumieniak O, Williams GH, et al. Uricacid and the de- velopment of hypertension : the normativeaging study [ J ]. Hyperten- sion,2011,48(6) :1031-1036.
9Feig DI, Nakagawa T, Karumanchi SA, et al. Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension [ J ]. Kidney Int,2012,66 ( 1 ) :281-287.
